

Oronzo Brunetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5752805/publications.pdf>

Version: 2024-02-01

109
papers

2,775
citations

172457

29
h-index

254184

43
g-index

123
all docs

123
docs citations

123
times ranked

4559
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721. | 3.1 | 85 |
| 2 | Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. Oncotarget, 2016, 7, 58649-58658. | 1.8 | 76 |
| 3 | Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. European Journal of Cancer, 2017, 86, 106-114. | 2.8 | 76 |
| 4 | CAFs and TGF- β 2 Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. Cancers, 2019, 11, 330. | 3.7 | 71 |
| 5 | Role of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance. Cancer Biology and Therapy, 2016, 17, 400-406. | 3.4 | 67 |
| 6 | Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. International Journal of Molecular Sciences, 2020, 21, 4427. | 4.1 | 67 |
| 7 | Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opinion on Pharmacotherapy, 2015, 16, 2719-2725. | 1.8 | 66 |
| 8 | Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. Cancers, 2019, 11, 942. | 3.7 | 66 |
| 9 | MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. Oncotarget, 2015, 6, 23323-23341. | 1.8 | 65 |
| 10 | Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?. Expert Opinion on Therapeutic Targets, 2015, 19, 1623-1635. | 3.4 | 58 |
| 11 | Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?. International Journal of Molecular Sciences, 2020, 21, 8305. | 4.1 | 58 |
| 12 | Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine. Cancers, 2021, 13, 2414. | 3.7 | 58 |
| 13 | Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies. Medicina (Lithuania), 2019, 55, 754. | 2.0 | 55 |
| 14 | Emerging Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Medicina (Lithuania), 2019, 55, 698. | 2.0 | 54 |
| 15 | Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib. Medicina (Lithuania), 2019, 55, 707. | 2.0 | 53 |
| 16 | Immunotherapeutic approaches for hepatocellular carcinoma. Oncotarget, 2017, 8, 33897-33910. | 1.8 | 50 |
| 17 | Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. Cancers, 2020, 12, 275. | 3.7 | 50 |
| 18 | Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma. Journal of Clinical Medicine, 2020, 9, 1594. | 2.4 | 49 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. <i>International Journal of Molecular Sciences</i> , 2017, 18, 418. | 4.1 | 47 |
| 20 | <i>In vitro</i> anti- μ myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. <i>British Journal of Haematology</i> , 2012, 157, 586-598. | 2.5 | 46 |
| 21 | Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects. <i>Biomedicines</i> , 2021, 9, 1075. | 3.2 | 46 |
| 22 | Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. <i>Cancers</i> , 2019, 11, 539. | 3.7 | 45 |
| 23 | Immune system and bone microenvironment: rationale for targeted cancer therapies. <i>Oncotarget</i> , 2020, 11, 480-487. | 1.8 | 45 |
| 24 | Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis. <i>Clinical and Experimental Medicine</i> , 2022, 22, 65-74. | 3.6 | 41 |
| 25 | Bone metastases in hepatocellular carcinoma: an emerging issue. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 333-342. | 5.9 | 38 |
| 26 | COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients?. <i>Frontiers in Oncology</i> , 2020, 10, 734. | 2.8 | 38 |
| 27 | The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112516. | 5.6 | 38 |
| 28 | Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations. <i>European Journal of Cancer</i> , 2019, 111, 94-106. | 2.8 | 36 |
| 29 | The Positive and Negative Immunoregulatory Role of B7 Family: Promising Novel Targets in Gastric Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10719. | 4.1 | 36 |
| 30 | Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 309-324. | 4.4 | 35 |
| 31 | MiR-144: A New Possible Therapeutic Target and Diagnostic/Prognostic Tool in Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2578. | 4.1 | 35 |
| 32 | A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery. <i>Genes</i> , 2021, 12, 1206. | 2.4 | 35 |
| 33 | Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation <i>in vitro</i> . <i>Experimental Hematology</i> , 2011, 39, 773-783.e1. | 0.4 | 33 |
| 34 | Inflammatory cells infiltrate and angiogenesis in locally advanced and metastatic cholangiocarcinoma. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13087. | 3.4 | 33 |
| 35 | The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. <i>Frontiers in Immunology</i> , 2021, 12, 676181. | 4.8 | 32 |
| 36 | Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. <i>Scientific Reports</i> , 2017, 7, 42499. | 3.3 | 30 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Mast cells and angiogenesis in pancreatic ductal adenocarcinoma. <i>Clinical and Experimental Medicine</i> , 2018, 18, 319-323. | 3.6 | 30 |
| 38 | The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5034. | 4.1 | 30 |
| 39 | Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. <i>Pancreas</i> , 2018, 47, 759-771. | 1.1 | 29 |
| 40 | Multimodal treatment of resectable pancreatic ductal adenocarcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 152-165. | 4.4 | 28 |
| 41 | Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). <i>ESMO Open</i> , 2017, 2, e000167. | 4.5 | 27 |
| 42 | Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 1718. | 3.7 | 27 |
| 43 | Second-line chemotherapy for advanced pancreatic cancer: Which is the best option?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 115, 1-12. | 4.4 | 26 |
| 44 | Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. <i>Cancers</i> , 2020, 12, 1729. | 3.7 | 26 |
| 45 | The regulatory role of autophagy-related miRNAs in lung cancer drug resistance. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112735. | 5.6 | 26 |
| 46 | Therapeutic approaches to myeloma bone disease: An evolving story. <i>Cancer Treatment Reviews</i> , 2012, 38, 787-797. | 7.7 | 25 |
| 47 | Skeletal Metastases of Unknown Primary: Biological Landscape and Clinical Overview. <i>Cancers</i> , 2019, 11, 1270. | 3.7 | 25 |
| 48 | Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. <i>Life Sciences</i> , 2021, 282, 119826. | 4.3 | 25 |
| 49 | Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2017, 12, 795-803. | 3.6 | 23 |
| 50 | The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. <i>Scientific Reports</i> , 2016, 6, 24136. | 3.3 | 22 |
| 51 | The combination effect of Prolin1 (CD133) suppression and Oxaliplatin treatment in colorectal cancer therapy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111364. | 5.6 | 21 |
| 52 | A scoping review on the potentiality of PD-L1-inhibiting microRNAs in treating colorectal cancer: Toward single-cell sequencing-guided biocompatible-based delivery. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112213. | 5.6 | 21 |
| 53 | Innovative surgical approaches for hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2016, 8, 591. | 2.0 | 21 |
| 54 | Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evidence Evaluation and Recommendations by the Italian Association of Medical Oncology (AIOM). <i>Cancers</i> , 2020, 12, 1681. | 3.7 | 20 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | NLRP3 Inflammasome From Bench to Bedside: New Perspectives for Triple Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1587. | 2.8 | 19 |
| 56 | Angiogenesis in adenosquamous cancer of pancreas. <i>Oncotarget</i> , 2017, 8, 95773-95779. | 1.8 | 19 |
| 57 | MicroRNAs and lncRNAs—A New Layer of Myeloid-Derived Suppressor Cells Regulation. <i>Frontiers in Immunology</i> , 2020, 11, 572323. | 4.8 | 17 |
| 58 | Evolving pancreatic cancer treatment: From diagnosis to healthcare management. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103571. | 4.4 | 17 |
| 59 | The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103674. | 4.4 | 17 |
| 60 | Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. <i>BMC Cancer</i> , 2015, 15, 692. | 2.6 | 16 |
| 61 | Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 453-461. | 3.4 | 15 |
| 62 | Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis. <i>Cancers</i> , 2020, 12, 534. | 3.7 | 15 |
| 63 | The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. <i>Targeted Oncology</i> , 2016, 11, 593-603. | 3.6 | 14 |
| 64 | Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , 2018, 104, 476-479. | 1.1 | 14 |
| 65 | A Systematic Review and Meta-Analysis on the Significance of TIGIT in Solid Cancers: Dual TIGIT/PD-1 Blockade to Overcome Immune-Resistance in Solid Cancers. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10389. | 4.1 | 14 |
| 66 | The cross-talk between tumor-associated macrophages and tumor endothelium: Recent advances in macrophage-based cancer immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112588. | 5.6 | 14 |
| 67 | Cholangiocarcinoma: new perspectives for new horizons. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1367-1383. | 3.0 | 13 |
| 68 | PD-L1 and Notch as novel biomarkers in pancreatic sarcomatoid carcinoma: a pilot study. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 1007-1016. | 3.4 | 13 |
| 69 | The potential predictive role of nuclear NHERF1 expression in advanced gastric cancer patients treated with epirubicin/oxaliplatin/capecitabine first line chemotherapy. <i>Cancer Biology and Therapy</i> , 2015, 16, 1140-1147. | 3.4 | 12 |
| 70 | Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1972-1976. | 0.5 | 12 |
| 71 | Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , 2020, 15, 773-785. | 3.6 | 12 |
| 72 | Novel lenalidomide-based combinations for treatment of multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 9-20. | 4.4 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. <i>Cancer Medicine</i> , 2017, 6, 1493-1499. | 2.8 | 11 |
| 74 | Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Società Italiana di Nefrologia (SIN) multidisciplinary consensus position paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 39-51. | 4.4 | 11 |
| 75 | Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. <i>Oncotarget</i> , 2017, 8, 66699-66708. | 1.8 | 11 |
| 76 | Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough. <i>Future Oncology</i> , 2017, 13, 2265-2275. | 2.4 | 10 |
| 77 | Targeting TGF- β -Mediated SMAD Signaling Pathway via Novel Recombinant Cytotoxin II: A Potent Protein from <i>Naja naja oxiana</i> Venom in Melanoma. <i>Molecules</i> , 2020, 25, 5148. | 3.8 | 10 |
| 78 | COVID Vaccination in Cancer Patients: What Vaccination Priority Strategies Should There Be?. <i>Frontiers in Oncology</i> , 2021, 11, 641388. | 2.8 | 10 |
| 79 | Silencing tumor-intrinsic CD73 enhances the chemosensitivity of NSCLC and potentiates the anti-tumoral effects of cisplatin: An in vitro study. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112370. | 5.6 | 10 |
| 80 | Immunotherapy of cancer in single-cell RNA sequencing era: A precision medicine perspective. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112558. | 5.6 | 10 |
| 81 | Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4681-4686. | 2.0 | 9 |
| 82 | A Systematic Review to Clarify the Prognostic Values of CD44 and CD44+CD24- Phenotype in Triple-Negative Breast Cancer Patients: Lessons Learned and The Road Ahead. <i>Frontiers in Oncology</i> , 2021, 11, 689839. | 2.8 | 9 |
| 83 | Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 6287. | 3.3 | 8 |
| 84 | Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. <i>Life</i> , 2021, 11, 1355. | 2.4 | 8 |
| 85 | The Italian Rare Pancreatic Exocrine Cancer Initiative. <i>Tumori</i> , 2019, 105, 353-358. | 1.1 | 7 |
| 86 | Long-term survival of an advanced colorectal cancer patient treated with Regorafenib: Case report and literature review. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2379-2383. | 0.5 | 7 |
| 87 | Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. <i>Frontiers in Oncology</i> , 2020, 10, 572329. | 2.8 | 7 |
| 88 | Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study. <i>Biomedicine and Pharmacotherapy</i> , 2022, 147, 112691. | 5.6 | 7 |
| 89 | Effects of Metformin and Vitamin D on Clinical Outcome in Cholangiocarcinoma Patients. <i>Oncology</i> , 2021, 99, 292-299. | 1.9 | 6 |
| 90 | Lights and Shadows on Managing Immune Checkpoint Inhibitors in Oncology during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1906. | 3.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Photodynamic Therapy with Zinc Phthalocyanine Inhibits the Stemness and Development of Colorectal Cancer: Time to Overcome the Challenging Barriers?. <i>Molecules</i> , 2021, 26, 6877. | 3.8 | 6 |
| 92 | Identification of Common and Distinct Pathways in Inflammatory Bowel Disease and Colorectal Cancer: A Hypothesis Based on Weighted Gene Co-Expression Network Analysis. <i>Frontiers in Genetics</i> , 2022, 13, 848646. | 2.3 | 6 |
| 93 | Genomic characterization of undifferentiated sarcomatoid carcinoma of the pancreas. <i>Human Pathology</i> , 2022, 128, 124-133. | 2.0 | 6 |
| 94 | Paraneoplastic Focal Segmental Glomerulosclerosis in Sarcomatoid Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, e66-e70. | 1.6 | 5 |
| 95 | Bone metastases in biliary cancers: A multicenter retrospective survey. <i>Journal of Bone Oncology</i> , 2018, 12, 33-37. | 2.4 | 5 |
| 96 | Expression and characterization of a novel recombinant cytotoxin II from <i>Naja naja oxiana</i> venom: A potential treatment for breast cancer. <i>International Journal of Biological Macromolecules</i> , 2020, 162, 1283-1292. | 7.5 | 5 |
| 97 | A Systematic Review on PD-1 Blockade and PD-1 Gene-Editing of CAR-T Cells for Glioma Therapy: From Deciphering to Personalized Medicine. <i>Frontiers in Immunology</i> , 2021, 12, 788211. | 4.8 | 5 |
| 98 | Molecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line Therapy. <i>Cancers</i> , 2019, 11, 749. | 3.7 | 4 |
| 99 | A Systematic Review of the Tumor-Infiltrating CD8+ T-Cells/PD-L1 Axis in High-Grade Glial Tumors: Toward Personalized Immuno-Oncology. <i>Frontiers in Immunology</i> , 2021, 12, 734956. | 4.8 | 4 |
| 100 | On the Management of Drug Interactions in the Course of Concomitant Treatments for COVID-19 and Antineoplastic Agents. <i>Frontiers in Oncology</i> , 2020, 10, 1340. | 2.8 | 3 |
| 101 | A Promising Role of TGF- β 2 Pathway in Response to Regorafenib in Metastatic Colorectal Cancer: A Case Report. <i>Medicina (Lithuania)</i> , 2021, 57, 1241. | 2.0 | 3 |
| 102 | Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. <i>Annals of Oncology</i> , 2017, 28, iii1-iii2. | 1.2 | 2 |
| 103 | Somatic BRCA Mutation in a Cholangiocarcinoma Patient for HBOC Syndrome Detection. <i>Frontiers in Oncology</i> , 2020, 10, 1292. | 2.8 | 2 |
| 104 | Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?. <i>Medical Oncology</i> , 2021, 38, 17. | 2.5 | 2 |
| 105 | Hepatocellular Cancer. <i>UNIPA Springer Series</i> , 2021, , 689-706. | 0.1 | 2 |
| 106 | Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a Therapeutic Option. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-7. | 1.9 | 1 |
| 107 | Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis. <i>Journal of Chemotherapy</i> , 2022, 34, 123-132. | 1.5 | 1 |
| 108 | Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy. <i>Molecules</i> , 2022, 27, 3545. | 3.8 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma?. Pancreas, 2020, 49, e11-e11. | 1.1 | 0 |